Table 3.

Association of HIVEP3 and SOX9 protein expression with the conventional clinicopathological characteristics in 98 patients with prostate cancer

Clinical features	Case number	HIVEP3		SOX9
		$\overline{X}\pm \text{s}$	P-value	$\overline{X}\pm \text{s}$	P-value
Age (years)
<60	62	3.63±0.77	0.952	7.32±0.98	0.528
≥60	36	3.64±0.83		7.19±1.00
Serum PSA Levels (ng/mL)
<4	16	3.82±0.92	0.318	7.52±1.08	0.293
≥4	82	3.60±0.76		7.24±0.96
Gleason score
<8	86	3.66±0.79	0.189	7.13±0.67	0.045
≥8	12	3.33±0.72		8.26±0.82
Clinical stage
<T2A	59	3.53±0.77	0.110	6.64±0.71	0.012
≥T2A	39	3.79±0.80		7.98±0.88
Metastasis
No	93	3.64±0.79	0.494	7.29±0.97	0.573
Yes	5	3.39±0.86		6.91 ±1.38
PSA failure
No	80	3.41±0.41	0.042	7.08±0.97	0.001
Yes	18	5.51±0.38		8.31 ±0.79

Note: Bold P-values are statistically significant.

Abbreviation: PSA, prostate-specific antigen.